What is this? This procurement is for R&D services to develop solutions to tackle the following challenge: To develop new, cost-effective, scalable, interoperable and non-intrusive Information and Communication Technology solutions for patients with chronic diseases, which provide self-management tools on adherence to their care plan and acknowledgement of their disease in order to increase their empowerment and management of life. To address the need for the solution to support patients with information, monitoring and data analysis of their disease evolution and communication with health professionals responsible for their care plan. The rationale of the focus by EMPATTICS on these chronic conditions is based on the high incidence, the social costs of these diseases, and the impact that adherence has on them, as well as empirically observed experiences of modifiable self-management behaviours and ICT use in relation to them. The intended EMPATTICS technological solutions will improve the level of knowledge and involvement of patients in the management of their disease and the prescribed treatments. This requires a multidisciplinary approach that encompasses the following aspects: — Increasing awareness of and knowledge about the importance of adherence, — Monitoring and evaluating patient adherence to agreed action plans, — Providing valuable information for the self-management of patient diseases, — Helping patients to develop healthy adaptive behaviours, — Facilitating communication between patients and health professionals. This is a common challenge shared by all procurers in the buyers group. Solutions shall be developed considering patient/carers and healthcare professionals experience and preferences during both the design and implementation phases. The products and innovations achieved at this PCP shall arise through co-operation and co-creation between health-care organisations, professionals and patients/families. Bidders are expected to consider the involvement of end-users very early in the product design process. It must be considered that target users will be patients of each of the three chronic disease groups chosen by EMPATTICS (i.e., Diabetes, COPD and Heart failure), a combination of these, and even a combination of these with other conditions, at different stages of their onset and with different personal profiles (adults, elderly dependent/active people, etc.). Owing to this, patients/carers will have specific contexts, circumstances, motivations, preferences, levels of health literacy and digital competences. As the requested solutions must be highly usable and adaptable, bidders shall pay special attention to the use of an iterative design process, especially in phase 1 but also in phases 2 and 3. The 3 selected diseases in the EMPATTICS project represent a major challenge for health systems across Europe, moving around 163 000 000 000 EUR in direct costs. The three diseases also impact on the wider social systems and economies of Member States, which are calling for adequate prevention and sustainable disease management technologies. The main quality/efficiency improvements sought for have been agreed on as being solutions that can be demonstrated during the testing phase: — A measurable increase in patients' empowerment; — A measurable increase in patients' adherence to the care plan; — A measurable difference in patients' clinical outcome; — A measurable decrease in resource consumption. The metrics and/or indicators which should be used to compare the results obtained before using the solutions and after using them are the following: — To evaluate the patients' empowerment, the PAM questionnaire will be used. — To evaluate the patients' adherence, the Moryski and Green test will be used. — To evaluate clinical outcome, the HbA1C, FEV and MLHQ will be measured for Diabetes, COPD and Heart Failure, respectively. — To evaluate the resource consumption, the number of events, number of exacerbations, number of hospitalisations, number of re-hospitalisations, days of stay and number of emergency visits will be used. All these data should be related to the three diseases chosen. To compare these metrics and/or indicators, historical control will be used. The comparator group will be those patients who are selected to test the solutions. These patients will have been treated and monitored for at least 1 year prior to the testing of the solutions and their data will be available through EMR or other databases (retrospective collection of data regarding demographics, clinical and economic outcomes). In order to achieve these improvements, the EMPATTICS solutions shall be designed for the personal use of the patients/carers suffering from chronic diseases, with the following functional requirements: Information 1. The solutions shall gather all required information from patient's agreed care plan. 2. The solutions shall support patients and/or carers in following and understanding their care plan. 3. The solutions shall support patients and/or carers to improve their understanding of the illness or illnesses in order to enable better self-management thereof. To do so, they shall at least provide access to suitable information sources adapted to each patient's profile. Monitoring 4. The solutions shall monitor relevant parameters related with patients' care plan, including vital signs, medication intake in any pharmaceutical form and behavioural data (i.e. physical activity, diet, etc.), and shall be able to do so automatically, with no intervention from the patient. 5. The solutions shall provide patients and/or carers with access to comprehensible information on their monitoring and the course of their illness. Data analysis 6. The solutions shall detect any failure to comply with the agreed care plan. 7. The solutions shall determine the principal reasons for any shortcoming in the monitoring of the agreed care plan or the patient's withdrawal. 8. The solutions shall learn from the data gathered from patients, in order to provide them with intelligent support which will help to ensure their continued compliance with the agreed care plan (at least through positive reinforcement regarding their achievements and health status). Communication between patients and health professionals 9. The solutions shall provide a channel for communication between patients and health professionals. It would also be desirable to provide a channel for communication between patients and other stakeholders in their care plan. 10. Subject to authorisation from patients, the solutions shall allow the professionals responsible for their care access to relevant the data gathered and generated by said solution. Confidentiality and Privacy 11. The solutions shall ensure that patients are the owners of all the information collected and stored by said solution. 12. Patients shall be able to decide over the solution, so as to preserve their privacy and prevent intrusiveness. Design 13. All those devices pertaining to the solutions which need to be carried by the patient shall be light, non-intrusive and easy to use, even for patients with scant digital skills. 14. The solutions shall include the option of a wearable device that always accompanies the patients, thus avoiding the possibility of forgetting said device. 15. The solutions shall be modular in order to be configured and used in line with patients' individual. 16. The solutions shall function in each of the buyers' languages. It would also be desirable if they could be easily adaptable to function in any other EU language. 17. The solutions shall be applicable to different chronic diseases (other than Diabetes, COPD and Heart Failure), as is or with minor modifications, and shall be flexible enough to cover comorbidities. 18. The solutions shall be sustainable in the medium and long term. Amortisation and maintenance costs must not be a hindrance to the deployment of services. 19. The solutions shall be capable of supporting large-scale deployment. 20. All data and information shall be stored taking into account the security, ethical and data management framework. 21. The solutions must have the potential to accommodate lacks of connectivity. 22. All requirements regarding interoperability, ICT standards, protection of personal health information, interfacing with local systems, etc., as described in section 4.4. Compliance criteria shall be taken into account. The PCP includes a limited set of prototype(s) and first test products or services resulting from the R&D in order to run the field testing by each successful phase 3 suppliers. Each contractor keeps ownership of the IPRs attached to the results it generates during the PCP implementation. The tendered price is expected to take this into account. Who is procuring? The procurement will be carried out jointly by the following organisations: Agencia Gallega para la Gestión del Conocimiento en Salud (ACIS), Central Denmark Region, Servicio Aragonés de la Salud and GCS SESAN (see www.empattics.eu). ACIS will act as the lead procurer and will coordinate and lead the joint procurement in the name and on behalf of the other organisations. How does it work? The procurement will take the form of a pre-commercial procurement (PCP) with a phased approach, under which R&D service contracts will be awarded to a number of R&D providers in parallel, in order to be able to compare competing alternative solutions. Each selected operator will conclude a framework agreement that covers three R&D phases. The 3 phases are: — solution design, — prototyping, — original development and validation and testing of a limited set of first products or services. After each phase, intermediate evaluations will be carried out to progressively select the best competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase. Testing is expected to take place in the four buyer regions. This testing may also serve as a first customer test reference for the contractors. Proposals may be submitted in English. All communication (before, during and after the procurement) can be made in English. For more information see: the project website (see www.empattics.eu), the open market consultation Q&A (see http://empattics.eu/call-for-tender/faq), />the PCP section on the Europa website (http://ec.europa.eu/digital-agenda/en/innovation-procurement), />or contact: />info@empattics.eu.
Plazo
El plazo para la recepción de ofertas era de 2017-08-31.
La contratación se publicó en 2017-06-29.
Proveedores
Los siguientes proveedores se mencionan en decisiones de adjudicación u otros documentos de contratación:
Anuncio de licitación (2017-06-29) Objeto Alcance de la contratación
Título: Servicios de investigación y desarrollo experimental
Cantidad o extensión: 187 500212 500
Metadatos del anuncio
Idioma original: inglés 🗣️
Tipo de documento: Anuncio de licitación
Naturaleza del contrato: Servicios
Reglamentación: Unión Europea
Vocabulario común de contratación pública (CPV)
Código: Servicios de investigación y desarrollo experimental📦
Procedimiento
Tipo de procedimiento: Procedimiento abierto
Tipo de oferta: Oferta para todos los lotes
Criterios de adjudicación
Oferta más económica
Autoridad contratante Identidad
País: España 🇪🇸
Tipo de poder adjudicador: Oficina/entidad regional o local
Nombre del poder adjudicador: Agencia Gallega para la Gestión del Conocimiento en Salud, ACIS (Health Knowledge Agency)
Dirección postal: av. Fernando de Casas Novas, 37, portal A-B, 1º piso
Código postal: 15707
Ciudad postal: Santiago de Compostela
Contacto
Dirección de internet: http://www.acis.sergas.es🌏
Correo electrónico: susana.fernandez.nocelo2@sergas.es📧
Teléfono: +34 981568055📞
Referencia Fechas
Fecha de envío: 2017-06-29 📅
Fecha límite de presentación: 2017-08-31 📅
Fecha de publicación: 2017-07-04 📅
Identificadores
Número de anuncio: 2017/S 125-255495
Se refiere al anuncio: 2016/S 174-313210
Número del DO-S: 125
Información complementaria
This procurement procedure is exempt from the EU public procurement directives as procurers do not retain all the benefits of the R&D (as a general rule, the IPR ownership remains with the contractors) and does not use the classical open procedure.
PCP is also exempted from the WTO Government Procurement Agreement (GPA) because this Agreement does not cover R&D services (the PCP being limited to such services — and any subsequent PPI or similar large-scale innovative procurements activities relating to commercial-scale supply of such solutions not being part of the PCP procurement).
The procurement does not constitute state aid under the EU state aid rules because it follows an open, transparent, competitive procedure with risk- and benefit-sharing at market price. (The division of all rights and obligations (including IPRs) and all selection and award criteria for all phases are published at the outset; the PCP is limited to R&D services and clearly separated from any potential follow-up PPI procurements; PCP contractors are not given any preferential treatment in a subsequent procurement for provision of the final products or services on a commercial scale).
This procurement procedure is exempt from the EU public procurement directives as procurers do not retain all the benefits of the R&D (as a general rule, the IPR ownership remains with the contractors) and does not use the classical open procedure.
PCP is also exempted from the WTO Government Procurement Agreement (GPA) because this Agreement does not cover R&D services (the PCP being limited to such services — and any subsequent PPI or similar large-scale innovative procurements activities relating to commercial-scale supply of such solutions not being part of the PCP procurement).
The procurement does not constitute state aid under the EU state aid rules because it follows an open, transparent, competitive procedure with risk- and benefit-sharing at market price. (The division of all rights and obligations (including IPRs) and all selection and award criteria for all phases are published at the outset; the PCP is limited to R&D services and clearly separated from any potential follow-up PPI procurements; PCP contractors are not given any preferential treatment in a subsequent procurement for provision of the final products or services on a commercial scale).
Objeto Alcance de la contratación
Breve descripción:
What is this? This procurement is for R&D services to develop solutions to tackle the following challenge:
To develop new, cost-effective, scalable, interoperable and non-intrusive Information and Communication Technology solutions for patients with chronic diseases, which provide self-management tools on adherence to their care plan and acknowledgement of their disease in order to increase their empowerment and management of life. To address the need for the solution to support patients with information, monitoring and data analysis of their disease evolution and communication with health professionals responsible for their care plan.
To develop new, cost-effective, scalable, interoperable and non-intrusive Information and Communication Technology solutions for patients with chronic diseases, which provide self-management tools on adherence to their care plan and acknowledgement of their disease in order to increase their empowerment and management of life. To address the need for the solution to support patients with information, monitoring and data analysis of their disease evolution and communication with health professionals responsible for their care plan.
The rationale of the focus by EMPATTICS on these chronic conditions is based on the high incidence, the social costs of these diseases, and the impact that adherence has on them, as well as empirically observed experiences of modifiable self-management behaviours and ICT use in relation to them.
The rationale of the focus by EMPATTICS on these chronic conditions is based on the high incidence, the social costs of these diseases, and the impact that adherence has on them, as well as empirically observed experiences of modifiable self-management behaviours and ICT use in relation to them.
The intended EMPATTICS technological solutions will improve the level of knowledge and involvement of patients in the management of their disease and the prescribed treatments. This requires a multidisciplinary approach that encompasses the following aspects:
The intended EMPATTICS technological solutions will improve the level of knowledge and involvement of patients in the management of their disease and the prescribed treatments. This requires a multidisciplinary approach that encompasses the following aspects:
— Increasing awareness of and knowledge about the importance of adherence,
— Monitoring and evaluating patient adherence to agreed action plans,
— Providing valuable information for the self-management of patient diseases,
— Helping patients to develop healthy adaptive behaviours,
— Facilitating communication between patients and health professionals.
This is a common challenge shared by all procurers in the buyers group.
Solutions shall be developed considering patient/carers and healthcare professionals experience and preferences during both the design and implementation phases. The products and innovations achieved at this PCP shall arise through co-operation and co-creation between health-care organisations, professionals and patients/families. Bidders are expected to consider the involvement of end-users very early in the product design process. It must be considered that target users will be patients of each of the three chronic disease groups chosen by EMPATTICS (i.e., Diabetes, COPD and Heart failure), a combination of these, and even a combination of these with other conditions, at different stages of their onset and with different personal profiles (adults, elderly dependent/active people, etc.). Owing to this, patients/carers will have specific contexts, circumstances, motivations, preferences, levels of health literacy and digital competences. As the requested solutions must be highly usable and adaptable, bidders shall pay special attention to the use of an iterative design process, especially in phase 1 but also in phases 2 and 3.
Solutions shall be developed considering patient/carers and healthcare professionals experience and preferences during both the design and implementation phases. The products and innovations achieved at this PCP shall arise through co-operation and co-creation between health-care organisations, professionals and patients/families. Bidders are expected to consider the involvement of end-users very early in the product design process. It must be considered that target users will be patients of each of the three chronic disease groups chosen by EMPATTICS (i.e., Diabetes, COPD and Heart failure), a combination of these, and even a combination of these with other conditions, at different stages of their onset and with different personal profiles (adults, elderly dependent/active people, etc.). Owing to this, patients/carers will have specific contexts, circumstances, motivations, preferences, levels of health literacy and digital competences. As the requested solutions must be highly usable and adaptable, bidders shall pay special attention to the use of an iterative design process, especially in phase 1 but also in phases 2 and 3.
The 3 selected diseases in the EMPATTICS project represent a major challenge for health systems across Europe, moving around 163 000 000 000 EUR in direct costs. The three diseases also impact on the wider social systems and economies of Member States, which are calling for adequate prevention and sustainable disease management technologies.
The 3 selected diseases in the EMPATTICS project represent a major challenge for health systems across Europe, moving around 163 000 000 000 EUR in direct costs. The three diseases also impact on the wider social systems and economies of Member States, which are calling for adequate prevention and sustainable disease management technologies.
The main quality/efficiency improvements sought for have been agreed on as being solutions that can be demonstrated during the testing phase:
— A measurable increase in patients' empowerment;
— A measurable increase in patients' adherence to the care plan;
— A measurable difference in patients' clinical outcome;
— A measurable decrease in resource consumption.
The metrics and/or indicators which should be used to compare the results obtained before using the solutions and after using them are the following:
— To evaluate the patients' empowerment, the PAM questionnaire will be used.
— To evaluate the patients' adherence, the Moryski and Green test will be used.
— To evaluate clinical outcome, the HbA1C, FEV and MLHQ will be measured for Diabetes, COPD and Heart Failure, respectively.
— To evaluate the resource consumption, the number of events, number of exacerbations, number of hospitalisations, number of re-hospitalisations, days of stay and number of emergency visits will be used. All these data should be related to the three diseases chosen.
— To evaluate the resource consumption, the number of events, number of exacerbations, number of hospitalisations, number of re-hospitalisations, days of stay and number of emergency visits will be used. All these data should be related to the three diseases chosen.
To compare these metrics and/or indicators, historical control will be used. The comparator group will be those patients who are selected to test the solutions. These patients will have been treated and monitored for at least 1 year prior to the testing of the solutions and their data will be available through EMR or other databases (retrospective collection of data regarding demographics, clinical and economic outcomes).
To compare these metrics and/or indicators, historical control will be used. The comparator group will be those patients who are selected to test the solutions. These patients will have been treated and monitored for at least 1 year prior to the testing of the solutions and their data will be available through EMR or other databases (retrospective collection of data regarding demographics, clinical and economic outcomes).
In order to achieve these improvements, the EMPATTICS solutions shall be designed for the personal use of the patients/carers suffering from chronic diseases, with the following functional requirements:
Information
1. The solutions shall gather all required information from patient's agreed care plan.
2. The solutions shall support patients and/or carers in following and understanding their care plan.
3. The solutions shall support patients and/or carers to improve their understanding of the illness or illnesses in order to enable better self-management thereof. To do so, they shall at least provide access to suitable information sources adapted to each patient's profile.
3. The solutions shall support patients and/or carers to improve their understanding of the illness or illnesses in order to enable better self-management thereof. To do so, they shall at least provide access to suitable information sources adapted to each patient's profile.
Monitoring
4. The solutions shall monitor relevant parameters related with patients' care plan, including vital signs, medication intake in any pharmaceutical form and behavioural data (i.e. physical activity, diet, etc.), and shall be able to do so automatically, with no intervention from the patient.
4. The solutions shall monitor relevant parameters related with patients' care plan, including vital signs, medication intake in any pharmaceutical form and behavioural data (i.e. physical activity, diet, etc.), and shall be able to do so automatically, with no intervention from the patient.
5. The solutions shall provide patients and/or carers with access to comprehensible information on their monitoring and the course of their illness.
Data analysis
6. The solutions shall detect any failure to comply with the agreed care plan.
7. The solutions shall determine the principal reasons for any shortcoming in the monitoring of the agreed care plan or the patient's withdrawal.
8. The solutions shall learn from the data gathered from patients, in order to provide them with intelligent support which will help to ensure their continued compliance with the agreed care plan (at least through positive reinforcement regarding their achievements and health status).
8. The solutions shall learn from the data gathered from patients, in order to provide them with intelligent support which will help to ensure their continued compliance with the agreed care plan (at least through positive reinforcement regarding their achievements and health status).
Communication between patients and health professionals
9. The solutions shall provide a channel for communication between patients and health professionals. It would also be desirable to provide a channel for communication between patients and other stakeholders in their care plan.
10. Subject to authorisation from patients, the solutions shall allow the professionals responsible for their care access to relevant the data gathered and generated by said solution.
Confidentiality and Privacy
11. The solutions shall ensure that patients are the owners of all the information collected and stored by said solution.
12. Patients shall be able to decide over the solution, so as to preserve their privacy and prevent intrusiveness.
Design
13. All those devices pertaining to the solutions which need to be carried by the patient shall be light, non-intrusive and easy to use, even for patients with scant digital skills.
14. The solutions shall include the option of a wearable device that always accompanies the patients, thus avoiding the possibility of forgetting said device.
15. The solutions shall be modular in order to be configured and used in line with patients' individual.
16. The solutions shall function in each of the buyers' languages. It would also be desirable if they could be easily adaptable to function in any other EU language.
17. The solutions shall be applicable to different chronic diseases (other than Diabetes, COPD and Heart Failure), as is or with minor modifications, and shall be flexible enough to cover comorbidities.
18. The solutions shall be sustainable in the medium and long term. Amortisation and maintenance costs must not be a hindrance to the deployment of services.
19. The solutions shall be capable of supporting large-scale deployment.
20. All data and information shall be stored taking into account the security, ethical and data management framework.
21. The solutions must have the potential to accommodate lacks of connectivity.
22. All requirements regarding interoperability, ICT standards, protection of personal health information, interfacing with local systems, etc., as described in section 4.4. Compliance criteria shall be taken into account.
The PCP includes a limited set of prototype(s) and first test products or services resulting from the R&D in order to run the field testing by each successful phase 3 suppliers.
Each contractor keeps ownership of the IPRs attached to the results it generates during the PCP implementation. The tendered price is expected to take this into account.
Who is procuring? The procurement will be carried out jointly by the following organisations: Agencia Gallega para la Gestión del Conocimiento en Salud (ACIS), Central Denmark Region, Servicio Aragonés de la Salud and GCS SESAN (see www.empattics.eu). ACIS will act as the lead procurer and will coordinate and lead the joint procurement in the name and on behalf of the other organisations.
Who is procuring? The procurement will be carried out jointly by the following organisations: Agencia Gallega para la Gestión del Conocimiento en Salud (ACIS), Central Denmark Region, Servicio Aragonés de la Salud and GCS SESAN (see www.empattics.eu). ACIS will act as the lead procurer and will coordinate and lead the joint procurement in the name and on behalf of the other organisations.
How does it work? The procurement will take the form of a pre-commercial procurement (PCP) with a phased approach, under which R&D service contracts will be awarded to a number of R&D providers in parallel, in order to be able to compare competing alternative solutions.
How does it work? The procurement will take the form of a pre-commercial procurement (PCP) with a phased approach, under which R&D service contracts will be awarded to a number of R&D providers in parallel, in order to be able to compare competing alternative solutions.
Each selected operator will conclude a framework agreement that covers three R&D phases.
The 3 phases are:
— solution design,
— prototyping,
— original development and validation and testing of a limited set of first products or services.
After each phase, intermediate evaluations will be carried out to progressively select the best competing solutions. The contractors with the best-value-for-money solutions will be offered a specific contract for the next phase.
Testing is expected to take place in the four buyer regions. This testing may also serve as a first customer test reference for the contractors.
Proposals may be submitted in English. All communication (before, during and after the procurement) can be made in English.
Valor estimado sin IVA: 187 500 💰
212 500 💰
Duración: 25 meses
Número de referencia: To be completed
Nombre del proyecto o programa financiado por la UE:
EMPATTICS project (EMpowering PAtients for a betTTer Information and Improvement of the Communication Systems), Horizon 2020 programme — Cofund — PCP.
Lugar de ejecución
Emplazamiento principal o lugar de actuación: EU countries and H2020 associated countries.
Información jurídica, económica, financiera y técnica Condiciones de participación
Habilitación para el ejercicio de la actividad profesional:
— If the bidder is a natural person, a certified copy of the national official identity card or of the passport shall be provided; if the bidder is a legal person, legal capacity shall be accredited by means of a certified copy of the deed or document of incorporation and/or amendment registered in the official Commercial Register when registration is compulsory in accordance with the applicable law. Otherwise, the capacity to act shall be accredited by means of a certified copy of the deed or document of incorporation and/or amendment, the founding act or the articles of association wherein the rules by which the bidder regulates its activity are stated, and registered, where applicable, in the corresponding official register.
Habilitación para el ejercicio de la actividad profesional
— If the bidder is a natural person, a certified copy of the national official identity card or of the passport shall be provided; if the bidder is a legal person, legal capacity shall be accredited by means of a certified copy of the deed or document of incorporation and/or amendment registered in the official Commercial Register when registration is compulsory in accordance with the applicable law. Otherwise, the capacity to act shall be accredited by means of a certified copy of the deed or document of incorporation and/or amendment, the founding act or the articles of association wherein the rules by which the bidder regulates its activity are stated, and registered, where applicable, in the corresponding official register.
— In the event of indirect representation, the powers under which the signatory of the proposal acts shall be demonstrated. If the represented party is a natural person, an authenticated copy of the notarised power of attorney shall be provided; if the represented party is a legal person, representation shall be accredited by the submission of a certified copy of the deed or document of incorporation and/or amendment, the founding act, or the articles of association from which the representation is derived. If the representation cannot be accredited through any of the described means, an authenticated copy of the notarised power of attorney shall be provided.
Habilitación para el ejercicio de la actividad profesional
— In the event of indirect representation, the powers under which the signatory of the proposal acts shall be demonstrated. If the represented party is a natural person, an authenticated copy of the notarised power of attorney shall be provided; if the represented party is a legal person, representation shall be accredited by the submission of a certified copy of the deed or document of incorporation and/or amendment, the founding act, or the articles of association from which the representation is derived. If the representation cannot be accredited through any of the described means, an authenticated copy of the notarised power of attorney shall be provided.
Should there be any doubt as to the legal capacity or representation, bidders may be requested to provide additional information and/or evidence.
Situación económica y financiera:
Bidders shall demonstrate that they have the necessary economic and financial solvency to perform R&D up to the original development of the first products or services and to commercially exploit the results of the PCP, including intangible results, in particular IPRs. The economic and financial solvency to assure the coverage of the costs related to the execution and implementation of the project must be accredited by means of at least one of the following forms of evidence:
Bidders shall demonstrate that they have the necessary economic and financial solvency to perform R&D up to the original development of the first products or services and to commercially exploit the results of the PCP, including intangible results, in particular IPRs. The economic and financial solvency to assure the coverage of the costs related to the execution and implementation of the project must be accredited by means of at least one of the following forms of evidence:
a) The annual accounts presented in the corresponding official Commercial Register referring to the last 3 available years. Bidders not obliged to present the accounts in an official Register may, as an alternative means of accreditation, provide duly legalised accounting books. Solvency shall be understood as accredited by those bidders whose annual net profits on the profit and loss account give an average of equal to or greater than 50 000 EUR.
a) The annual accounts presented in the corresponding official Commercial Register referring to the last 3 available years. Bidders not obliged to present the accounts in an official Register may, as an alternative means of accreditation, provide duly legalised accounting books. Solvency shall be understood as accredited by those bidders whose annual net profits on the profit and loss account give an average of equal to or greater than 50 000 EUR.
b) Statement issued by an accredited financial institution attesting the availability by the bidder of an amount equal or greater than 50 000 EUR or the existence of a credit granted for the same amount.
c) Statement made by one of more investors providing a financial guarantee in an amount equal or greater than 50 000 EUR for the performance of the contract.
In spite of the above, for recently established businesses which have not yet existed for three financial years for which accounts have been closed, the annual accounts for one year only – if available – and a simple declaration on turnover will be required but supplemented by at least one of the following declarations providing a financial guarantee for the performance of the contract: bank declaration or declaration from an insurance company.
In spite of the above, for recently established businesses which have not yet existed for three financial years for which accounts have been closed, the annual accounts for one year only – if available – and a simple declaration on turnover will be required but supplemented by at least one of the following declarations providing a financial guarantee for the performance of the contract: bank declaration or declaration from an insurance company.
Niveles mínimos de normas: Section above.
Capacidad técnica y profesional:
Bidders shall demonstrate that they have the necessary technical and professional solvency to perform the contract to an appropriate quality standard. More precisely, bidders shall accredit that they possess the necessary experience and human and technical resources to perform R&D up to the original development of the first products or services and to commercially exploit the results of the PCP, including intangible results, in particular IPRs. This technical and professional solvency must be accredited by means of the following evidence:
Bidders shall demonstrate that they have the necessary technical and professional solvency to perform the contract to an appropriate quality standard. More precisely, bidders shall accredit that they possess the necessary experience and human and technical resources to perform R&D up to the original development of the first products or services and to commercially exploit the results of the PCP, including intangible results, in particular IPRs. This technical and professional solvency must be accredited by means of the following evidence:
A list of the main services or works similar to the present contract (see the last paragraph of this section) made by the bidder in the last 5 years, including amounts, dates and the recipients, public or private. In the description of the services or works carried out, bidders should detail the results obtained and the way in which they were commercially exploited. In the case of bidders whose activity period does not cover the last 5 years, the list of services or works will be those of the period corresponding to the bidder's activity. The required solvency shall be understood to be accredited by the satisfactory completion of at least one service or work on the indicated fields.
A list of the main services or works similar to the present contract (see the last paragraph of this section) made by the bidder in the last 5 years, including amounts, dates and the recipients, public or private. In the description of the services or works carried out, bidders should detail the results obtained and the way in which they were commercially exploited. In the case of bidders whose activity period does not cover the last 5 years, the list of services or works will be those of the period corresponding to the bidder's activity. The required solvency shall be understood to be accredited by the satisfactory completion of at least one service or work on the indicated fields.
In spite of the above, recently established businesses such as start-ups may also compete in this PCP procedure, even if they have not satisfactorily completed any service or work similar to the purpose of the present contract provided that the personnel assigned to the execution of the project do have the required experience. In such cases, in addition to the list of the services or works referred to in the previous paragraph performed during their period of activity, bidders shall submit a list of the services and works carried out by the staff allocated to the performance of the project in the previous 5 years and the profiles and curricula of said personnel, which shall contain a detailed description of their academic background and their previous professional experience. In this case, the required solvency shall be understood to be accredited by the satisfactory completion by the personnel allocated to the project of at least one service or work in the aforementioned areas or by the execution of a research project in an academic field similar to the purpose of the present contract.
In spite of the above, recently established businesses such as start-ups may also compete in this PCP procedure, even if they have not satisfactorily completed any service or work similar to the purpose of the present contract provided that the personnel assigned to the execution of the project do have the required experience. In such cases, in addition to the list of the services or works referred to in the previous paragraph performed during their period of activity, bidders shall submit a list of the services and works carried out by the staff allocated to the performance of the project in the previous 5 years and the profiles and curricula of said personnel, which shall contain a detailed description of their academic background and their previous professional experience. In this case, the required solvency shall be understood to be accredited by the satisfactory completion by the personnel allocated to the project of at least one service or work in the aforementioned areas or by the execution of a research project in an academic field similar to the purpose of the present contract.
Note: EMPATTICS considers a service or work similar to the present contract the previous realisation of R&D services or R&D projects in the following fields:
— R&D services or R&D projects that pursue to develop ICT technologies that support Patient Empowerment initiatives or increase their adherence to treatments.
— R&D services or R&D projects in mobile-health and e-health.
— R&D services or R&D projects performed in other sectors or markets that pursue to develop technologies based on big data, virtual reality, wearables, serious games, artificial intelligence, smart sensors or Machine Learning.
Ejecución del contrato
Principales condiciones de financiación y modalidades de pago y/o referencia a las disposiciones pertinentes por las que se rigen:
In phase 1, a single payment shall be made once the EMPATTICS Monitoring Board has verified the satisfactory completion of the phase and the Buyers Evaluation Board has given its approval.
In phases 2 and 3, an interim payment of the 50 % of the value of the relevant phase contract shall be made after the satisfactory evaluation by the EMPATTICS Monitoring Board of the interim milestones and deliverables submitted by the bidders and of the approval of the Buyers Evaluation Board.
Principales condiciones de financiación y modalidades de pago y/o referencia a las disposiciones pertinentes por las que se rigen
In phases 2 and 3, an interim payment of the 50 % of the value of the relevant phase contract shall be made after the satisfactory evaluation by the EMPATTICS Monitoring Board of the interim milestones and deliverables submitted by the bidders and of the approval of the Buyers Evaluation Board.
In phases 2 and 3, the payment of the balance shall be made once the EMPATTICS Monitoring Board has verified the satisfactory completion of each phase and the Buyers Evaluation Board has given its approval.
Forma jurídica que adoptará la agrupación de operadores económicos adjudicataria del contrato:
Tenders may be submitted by any type of natural or legal persons (including properly registered non-profit entities, such as Universities), as a single entity or in collaboration with others. The latter can involve either submitting a joint tender or subcontracting, or a combination of the 2 approaches.
Forma jurídica que adoptará la agrupación de operadores económicos adjudicataria del contrato
Tenders may be submitted by any type of natural or legal persons (including properly registered non-profit entities, such as Universities), as a single entity or in collaboration with others. The latter can involve either submitting a joint tender or subcontracting, or a combination of the 2 approaches.
Otras condiciones particulares:
— At least 70 % of the total value of activities covered by the contract must be performed in the EU Member States or in H2020 associated countries. The principal R&D staff working on each specific contract must be located in the EU Member States or H2020 associated countries.
— At least 70 % of the total value of activities covered by the contract must be performed in the EU Member States or in H2020 associated countries. The principal R&D staff working on each specific contract must be located in the EU Member States or H2020 associated countries.
Nombres y cualificaciones profesionales del personal ✅
Procedimiento
Número de operadores del acuerdo marco: 6
Duración del acuerdo marco en meses: 25
Plazo de validez de la oferta: 2017-10-24 📅
Fecha de apertura de ofertas: 2017-09-11 📅
Lugar de apertura:
Avda. Fernando de Casas Novoa, n.º 37, Portal A-B, 1º andar 15707, Santiago de Compostela, A Coruña.
Lugar: Avda. Fernando de Casas Novoa, n.º 37, Portal A-B, 1º andar 15707, Santiago de Compostela, A Coruña.
Información sobre las personas autorizadas y el procedimiento de apertura: Bidders can be present at the opening of envelops B and C.
Lenguas
Lengua: inglés 🗣️
Autoridad contratante Identidad
Nombre del poder adjudicador: Region Midtjylland, CDR
Dirección postal: Skottenborg 26
Ciudad postal: Viborg
Código postal: 8800
País: Dinamarca 🇩🇰
Nombre del poder adjudicador: Servicio Aragonés de la Salud
Dirección postal: Via Universitas, 34
Ciudad postal: Zaragoza
Código postal: 50071
Nombre del poder adjudicador: Groupment de cooperation sanitaire pour le developpement des systèmes d'information partagés en Île-de-France, GCS-SESAN, GCS D-SISIF
Dirección postal: 10 rue du Faubourg-Montmartre
Ciudad postal: Paris
Código postal: 75009
País: Francia 🇫🇷 Contacto
Punto de contacto: Susana Fernandez Nocelo
Dirección del perfil de comprador: http://www.empattics.eu🌏
Correo electrónico: empattics@sergas.es📧
Referencia Fechas
Fecha de publicación: 2016-09-09 📅
2016-09-16 📅
Identificadores
Número de referencia atribuido por el poder adjudicador: To be completed
Número de anuncio en el DO S: 2016/S 174-313210
2016/S 179-321475
Información complementaria
This procurement procedure is exempt from the EU public procurement directives as procurers do not retain all the benefits of the R&D (as a general rule, the IPR ownership remains with the contractors) and does not use the classical open procedure.
PCP is also exempted from the WTO Government Procurement Agreement (GPA) because this Agreement does not cover R&D services (the PCP being limited to such services — and any subsequent PPI or similar large-scale innovative procurements activities relating to commercial-scale supply of such solutions not being part of the PCP procurement).
PCP is also exempted from the WTO Government Procurement Agreement (GPA) because this Agreement does not cover R&D services (the PCP being limited to such services — and any subsequent PPI or similar large-scale innovative procurements activities relating to commercial-scale supply of such solutions not being part of the PCP procurement).
The procurement does not constitute state aid under the EU state aid rules because it follows an open, transparent, competitive procedure with risk- and benefit-sharing at market price. (The division of all rights and obligations (including IPRs) and all selection and award criteria for all phases are published at the outset; the PCP is limited to R&D services and clearly separated from any potential follow-up PPI procurements; PCP contractors are not given any preferential treatment in a subsequent procurement for provision of the final products or services on a commercial scale).
The procurement does not constitute state aid under the EU state aid rules because it follows an open, transparent, competitive procedure with risk- and benefit-sharing at market price. (The division of all rights and obligations (including IPRs) and all selection and award criteria for all phases are published at the outset; the PCP is limited to R&D services and clearly separated from any potential follow-up PPI procurements; PCP contractors are not given any preferential treatment in a subsequent procurement for provision of the final products or services on a commercial scale).
Información complementaria Órgano de revisión
Nombre: Agencia Gallega para la Gestión del Conocimiento en Salud, ACIS (Health Knowledge Agency)
Dirección postal: av. Fernando de Casas Novoa, nº 37, portal A-B, 1º andar
Ciudad postal: Santiago de Compostela
Código postal: 15707
País: España 🇪🇸
Correo electrónico: empattics@sergas.es📧
Teléfono: +34 981568055📞
Dirección de internet: www.acis.sergas.es🌏
Información sobre los plazos de procedimientos de recurso:
15.9.2017 — Deadline for remedying deficiencies (Envelop A).
16.10.2017 — Deadline for submitting appeals.
Organismo responsable de los procedimientos de mediación Igual que: Órgano de revisión
Fuente: OJS 2017/S 125-255495 (2017-06-29)
Información complementaria (2017-07-12) Objeto Metadatos del anuncio
Tipo de documento: Información complementaria
Referencia Fechas
Fecha de envío: 2017-07-12 📅
Fecha límite de presentación: 2017-09-05 📅
Fecha de publicación: 2017-07-14 📅
Identificadores
Número de anuncio: 2017/S 133-273312
Se refiere al anuncio: 2017/S 125-255495
Número del DO-S: 133
Fuente: OJS 2017/S 133-273312 (2017-07-12)
Anuncio de adjudicación de contrato (2017-11-23) Objeto Alcance de la contratación
Valor total de la contratación: 37 500 💰
Metadatos del anuncio
Tipo de documento: Anuncio de adjudicación de contrato
Procedimiento
Tipo de oferta: No procede
Autoridad contratante Identidad
Dirección postal: av. de Fernando de Casas Novoa, 37, Portal A-B, 1º piso
Referencia Fechas
Fecha de envío: 2017-11-23 📅
Fecha de publicación: 2017-11-25 📅
Identificadores
Número de anuncio: 2017/S 227-474182
Número del DO-S: 227
Información complementaria
Patient engagement design and devices integrator.
1️⃣
Fecha de celebración del contrato: 2017-10-25 📅
Nombre: Everis spain, slu
Dirección postal: Avda de Manoteras, 52
Ciudad postal: Madrid
Código postal: 28050
País: España 🇪🇸
Correo electrónico: acoruna@everis.com📧
2️⃣
Nombre: Sanna Consortium (Lead Contractor: Health Insight Solutions GmbH)
Dirección postal: Konrad-Zuse-Platz, 8
Ciudad postal: Munich
Código postal: 81829
País: Alemania 🇩🇪
Correo electrónico: m.dangelantonio@health-insight.de📧
3️⃣
Nombre: PHM Consortium (Lead Contractor: Camelot Biomedical Systems, SRL)
Dirección postal: Via Al Ponte Reale, 2/20
Ciudad postal: Genoa
Código postal: 16124
País: Italia 🇮🇹
Correo electrónico: info@camelotbio.com📧
4️⃣
Nombre: Linkcare Health Services, SL
Dirección postal: C/ Roger de Llúria, 50, Sobreático A
Ciudad postal: Barcelona
Código postal: 08009
Correo electrónico: jose.sanchez@linkcare.es📧
6️⃣
Nombre: Disoles LAB Consortium (Lead Contractor: Laboratorios del Doctor Esteve SAU)
Dirección postal: Avda Mare de Déu de Montserrat, 221
Código postal: 08041
Correo electrónico: licitaciones@esteve.es📧 Información sobre licitaciones
Número de ofertas recibidas: 21
Autoridad contratante Identidad
Dirección postal: Via Universitas 34
Nombre del poder adjudicador: Groupment de cooperation sanitaire pour le developpement des systèmes d'information partagés en Île-de-France, CGCS-SESAN, GCS D-SISIF
Dirección postal: 10 Rue du Faubourg-Montmartre
Información complementaria Órgano de revisión
Avda. Fernando de Casas Novoa, n.º 37 | Portal A-B | 1º andar
Fuente: OJS 2017/S 227-474182 (2017-11-23)